Targeting of the Hedgehog pathway in myeloid malignancies: still a worthy chase?

British Journal of Haematology

Volumn 170, Issue 3, 2015, Pages 323-335

  Khan, Alesia A ^a   Harrison, Claire N ^a   McLornan, Donal P ^a,b  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

cell signalling; Hedgehog; myeloid leukaemia; pathways; smoothened

Indexed keywords

PROTEIN INHIBITOR; SMO PROTEIN INHIBITOR; SONIC HEDGEHOG PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; TUMOR PROTEIN;

ACUTE MYELOBLASTIC LEUKEMIA; CARCINOGENESIS; CHRONIC MYELOID LEUKEMIA; DISEASE ACTIVITY; DISEASE ASSOCIATION; DOWN REGULATION; DRUG RESPONSE; HEMATOLOGIC DISEASE; HEMATOPOIESIS; HUMAN; MOLECULAR PATHOLOGY; MYELODYSPLASTIC SYNDROME; MYELOID LEUKEMIA; MYELOPROLIFERATIVE NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG DELIVERY SYSTEM; DRUG EFFECTS; GENETICS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, MYELOID, ACUTE; METABOLISM; MYELODYSPLASTIC SYNDROMES; PATHOLOGY; PRIMARY MYELOFIBROSIS; PROCEDURES;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HEDGEHOG PROTEINS; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, MYELOID, ACUTE; MYELODYSPLASTIC SYNDROMES; NEOPLASM PROTEINS; PRIMARY MYELOFIBROSIS; SIGNAL TRANSDUCTION;

EID: 84942101897     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13426     Document Type: Review

References (86)

1. Alonso-Dominguez, J., Grinfeld, J., Alikian, M., Marin, D., Reid, A., Daghistani, M., Hedgley, C., O'Brien, S., Clark, R., Apperley, J., Foroni, L. & Gerrard, G. (2015) PTCH1 expression at diagnosis predicts imatinib failure in chronic myeloid leukaemia patients in chronic phase. American Journal of Hematology, 90, 20–26.
2. Atwood, S., Li, M., Lee, A., Tang, J. & Oro, A. (2013) GLI activation by atypical protein kinase C ?/? regulates the growth of basal cell carcinomas. Nature, 494, 484–488.
3. Bermudez, O., Hennen, E., Koch, I., Lindner, M. & Eickelberg, O. (2013) Gli1 mediates lung cancer cell proliferation and Sonic Hedgehog-dependent mesenchymal cell activation. PLoS ONE, 8, e63226.
4. Bhagwat, N., Keller, M., Rampal, R., Koppikar, P., Shank, K., De Stanchina, E., Rose, K., Amakye, D. & Levine, R. (2013) Improved efficacy of combination of JAK2 and hedgehog inhibitors in myelofibrosis [abstract]. Blood, 122, s666.
5. Blotta, S., Jakubikova, J., Calimeri, T., Roccaro, A., Amodio, N., Azab, A., Foresta, U., Mitsiades, C., Rossi, M., Todoerti, K., Molica, S., Morabito, F., Neri, A., Tagliaferri, P., Tassone, P., Anderson, K. & Munshi, N. (2012) Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma. Blood, 120, 5002–5013.
6. Buonamici, S., Williams, J., Morrissey, M., Wang, A., Guo, R., Vattay, A., Hsiao, K., Yuan, J., Green, J., Ospina, B., Yu, Q., Ostrom, L., Fordjour, P., Anderson, D., Monahan, J., Kelleher, J., Peukert, S., Pan, S., Wu, X., Maira, S., García-Echeverría, C., Briggs, K., Watkins, D., Yao, Y., Lengauer, C., Warmuth, M., Sellers, WR. & Dorsch, M. (2010) Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma. Science Translational Medicine, 2, 51ra70.
7. Campbell, V., Tholouli, E., Quigley, M., Keilty, K., McGovern, K., Read, M., Kutok, J. & Byers, R. (2012) Evidence that activated hedgehog signaling predicts for poor clinical outcome in acute myeloid leukemia. Blood, 120, 1441.
8. Chang, H., Li, Q., Moraes, R., Lewis, M. & Hamel, P. (2010) Activation of ERK by sonic hedgehog is independent of canonical hedgehog signaling. International Journal of Biochemistry and Cell Biology, 42, 1462–1471.
9. Chen, Y., Hu, Y., Michaels, S., Segal, D., Brown, D. & Li, S. (2009) Inhibitory effects of omacetaxine on leukemic stem cells and BCR-ABL-induced chronic myeloid leukemia and acute lymphoblastic leukemia in mice. Leukemia, 23, 1446–1454.
10. Cridland, S., Keys, J., Papathanasiou, P. & Perkins, A. (2009) Indian hedgehog supports definitive erythropoiesis. Blood Cells Molecules and Diseases, 43, 149–155.
11. Das, S., Samant, R. & Shevde, L. (2013) Nonclassical activation of Hedgehog signalling enhances multidrug resistance and makes cancer cells refractory to Smoothened-targeting Hedgehog inhibition. Journal of Biological Chemistry, 288, 11824–11833.
12. Decker, S., Zirlik, K., Djebatchie, L., Hartmann, D., Ihorst, G., Schmitt-Graeff, A., Herchenbach, D., Jumaa, H., Warmuth, M., Veelken, H. & Dierks, C. (2012) Trisomy 12 and elevated GLI1 and PTCH1 transcript levels are biomarkers for Hedgehog-inhibitor responsiveness in CLL. Blood, 119, 997–1007.
13. Desch, P., Asslaber, D., Kern, D., Schnidar, H., Mangelberger, D., Alinger, B., Stoecher, M., Hofbauer, S., Neureiter, D., Tinhofer, I., Aberger, F., Hartmann, T. & Greil, R. (2010) Inhibition of GLI, but not smoothened, induces apoptosis in chronic lymphocytic leukemia cells. Oncogene, 29, 4885–4895.
14. Dierks, C., Grbic, J., Zirlik, K., Beigi, R., Englund, N., Guo, G., Veelken, H., Engelhardt, M., Mertelsmann, R., Kelleher, J., Schultz, P. & Warmuth, M. (2007) Essential role of stromally induced hedgehog signaling in B-cell malignancies. Nature Medicine, 13, 944–951.
15. Dierks, C., Beigi, R., Guo, G., Zirlik, K., Stegert, M., Manley, P., Trussell, C., Schmitt-Graeff, A., Landwerlin, K., Veelken, H. & Warmuth, M. (2008) Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation. Cancer Cell, 14, 238–249.
16. Dijkgraaf, G., Alicke, B., Weinmann, L., Januario, T., West, K., Modrusan, Z., Burdick, D., Goldsmith, R., Robarge, K., Sutherlin, D., Scales, S., Gould, S., Yauch, R. & de Sauvage, F. (2011) Small molecule inhibition of GDC-0449 refractory smoothened mutants and downstream mechanisms of drug resistance. Cancer Research, 71, 435–444.
17. Dyer, M., Farrington, S., Mohn, D., Munday, J. & Baron, M. (2001) Indian hedgehog activates hematopoiesis and vasculogenesis and can respecify prospective neurectodermal cell fate in the mouse embryo. Development, 128, 1717–1730.
18. Epstein, E. (2008) Basal cell carcinomas: attack of the hedgehog. Nature Reviews Cancer, 10, 743–754.
19. Fiskus, W., Sharma, S., Qi, J., Shah, B., Devaraj, S., Leveque, C., Portier, B., Iyer, S., Bradner, J. & Bhalla, K. (2014) BET protein antagonist JQ1 Is synergistically lethal with FLT3 Tyrosine kinase inhibitor (TKI) and Overcomes resistance to FLT3-TKI in AML cells expressing FLT-ITD. Molecular Cancer Therapeutics, 13, 2315–2327.
20. Fukushima, N., Minami, Y., Hayakawa, F., Hayakawa, F., Kiyoi, H., Sadarangani, A., Jamieson, C. & Naoe, T. (2013) Treatment with hedgehog inhibitor, PF-04449913, attenuates leukemia-initiation potential in acute myeloid leukemia cells. Blood, 122, 1649.
21. Gao, J., Graves, S., Koch, U., Liu, S., Jankovic, V., Buonamici, S., El Andaloussi, A., Nimer, S., Kee, B., Taichman, R., Radtke, F. & Aifantis, I. (2009) Hedgehog signaling is dispensable for adult hematopoietic stem cell function. Cell Stem Cell, 4, 548–558.
22. Gendreau, S., Hawkins, D., Ho, C.-P., Lewin, A., Lin, T., Merchant, A. & Rowley, R. (2009) Preclinical characterization of BMS-833923 (XL139), a Hedgehog (HH) pathway inhibitor in early clinical development. Molecular Cancer Therapeutics, 8, B192.
23. Gering, M. & Patient, R. (2005) Hedgehog signaling is required for adult blood stem cell formation in zebrafish embryos. Developmental Cell, 3, 389–400.
24. Graham, S., Jorgensen, H., Allan, E., Pearson, C., Alcorn, M., Richmond, L. & Holyoake, T. (2002) Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood, 99, 319–325.
25. Gupta, V., Koschmieder, S., Harrison, H., Cervantes, F., Heidel, F., Drummond, M., Rey, J., Hurh, E., Bao, W., Rampersad, A., Kalambakas, S. & Vannucchi, A. (2014) Phase 1b dose-escalation study of sonidegib (LDE225) in combination with ruxolitinib (INC424) in patients with myelofibrosis. [abstract]. Blood, 124, s634.
26. Hahn, H., Wicking, C., Zaphiropoulous, P., Gailani, M., Shanley, S., Chidambaram, A., Vorechovsky, I., Holmberg, E., Unden, A., Gillies, S., Negus, K., Smyth, I., Pressman, C., Leffell, D., Gerrard, B., Goldstein, A., Deanemail, M., Toftgard, R., Chenevix-Trench, G., Wainwright, B. & Bale, A. (1996) Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell, 85, 841–851.
27. Hegde, G., Peterson, K., Emanuel, K., Mittal, A., Joshi, A., Dickinson, J., Kollessery, G., Bociek, R., Bierman, P., Vose, J., Weisenburger, D. & Joshi, S. (2008) Hedgehog-induced survival of B-cell chronic lymphocytic leukemia cells in a stromal cell microenvironment: a potential new therapeutic target. Molecular Cancer Research, 12, 1928–1936.
28. Herrmann, H., Blatt, K., Shi, J., Gleixner, K.V., Cerny-Reiterer, S., Müllauer, L., Vakoc, C.R., Sperr, W.R., Horny, H.P., Bradner, J.E., Zuber, J. & Valent, P. (2012) Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia AML. Oncotarget, 3, 1588–1599.
29. Hickey, F., England, K. & Cotter, T. (2005) Bcr-Abl regulates osteopontin transcription via Ras, PI-3K, aPKC, Raf-1, and MEK. Journal of Leukocyte Biology, 78, 289–300.
30. Hooper, J.E. & Scott, M.P. (2005) Communicating with Hedgehogs. Nature Reviews Molecular Cell Biology, 6, 306–317.
31. Huang, K., Ding, B., Zhong, Q., Jiang, X., Li, X., Wang, Z. & Meng, F.Y. (2014) Hh/IGF-1R/PI3K/Akt/MRP1 Pathway induce refractory acute myeloid leukemia and its targeting therapy. Blood, 124, 3612.
32. Irvine, D. & Copland, M. (2012) Targeting hedgehog in hematologic malignancy. Blood, 119, 2196–2204.
33. Irvine, D.A., Zhang, B., Allan, E.K., Holyoake, T.L., Dorsch, M., Manley, P.W., Bhatia, R. & Copland, M. (2009) Combination of the hedgehog pathway inhibitor LDE225 and nilotinib eliminates chronic myeloid leukemia stem and progenitor cells. Blood, 114, 1428.
34. Jackson-Fisher, A., Whalen, P., Elliott, M., McMahon, M., Chen, E., Zheng, X., Ozeck, M., Huang, D., Lira, P., Lee, J., Zhang, C., Lam, J., Spilker, M., Deng, S., Lappin, P., Venne, P., Heinlein, C., Schairer, A., McLachlan, K. & VanArsdale, T. (2014) Interrogating hedgehog pathway and smoothened inhibition by PF-04449913 in patient-derived acute myeloid leukemia models. Cancer Research, 74, 1958.
35. Jagani, Z., Dorsch, M. & Warmuth, M. (2010) Hedgehog pathway activation in chronic myeloid leukemia. Cell Cycle, 9, 3449–3456.
36. Jamieson, C., Cortes, J., Oehler, V., Baccarani, M., Kantarjian, H., Papayannidis, C., Rice, K., Zhang, X., Shaik, N., Courtney, R., Levin, W. & Martinelli, G. (2011) Phase 1 dose-escalation study of PF-04449913, an oral hedgehog (Hh) inhibitor, in patients with select hematologic malignancies [abstract]. Blood, 118, s424.
37. Jenkins, D. (2009) Hedgehog signaling: emerging evidence for non-canonical pathways. Cellular Signal, 21, 1023–1034.
38. Johnson, R.L. & Scott, M.P. (1998) New players and puzzles in the Hedgehog signaling pathway. Current Opinion in Genetics and Development, 8, 450–456.
39. Johnson, R., Rothman, A., Xie, J., Goodrich, L., Bare, J., Bonifas, J., Quinn, A., Myers, R., Cox, D., Epstein, E. & Scott, M. (1996) Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Science, 272, 1668–1671.
40. Katagiri, S., Tauchi, T., Okabe, S., Minami, Y., Kimura, S., Maekawa, T., Naoe, T. & Ohyashiki, K. (2013) Combination of ponatinib with Hedgehog antagonist vismodegib for therapy-resistant BCR-ABL1-positive leukemia. Clinical Cancer Research, 19, 1422–1432.
41. Kean, S. (2009) Medicine. Disrupting Hedgehog may reverse advanced cancer, if only temporarily. Science, 325, 1188.
42. Kim, J., Singh, R., Cho-Vega, J., Drakos, E., Davuluri, Y., Khokhar, F., Fayad, L., Medeiros, L. & Vega, F. (2009) Sonic hedgehog signaling proteins and ATP-binding cassette G2 are aberrantly expressed in diffuse large B-cell lymphoma. Modern Pathology, 22, 1312–1320.
43. Kobune, M., Takimoto, R., Murase, K., Iyama, S., Sato, T., Kikuchi, S., Kawano, Y., Miyanishi, K., Sato, Y., Niitsu, Y. & Kato, J. (2009) Drug resistance is dramatically restored by hedgehog inhibitors in CD34 + leukemic cells. Cancer Science, 100, 948–955.
44. Kobune, M., Iyama, S., Kikuchi, S., Horiguchi, H., Sato, T., Murase, K., Kawano, Y., Takada, K., Ono, K., Kamihara, Y., Hayashi, T., Miyanishi, K., Sato, Y., Takimoto, R. & Kato, J. (2012) Stromal cells expressing hedgehog-interacting protein regulate the proliferation of myeloid neoplasms. Blood Cancer Journal, 7, e87.
45. Kunkalla, K., Liu, Y., Qu, C., Leventaki, V., Agarwal, N., Singh, R. & Vega, F. (2013) Functional inhibition of BCL2 is needed to increase the susceptibility to apoptosis to SMO inhibitors in diffuse large B-cell lymphoma of germinal center subtype. Annals of Hematology, 92, 777–787.
46. Lauth, M. & Toftgard, R. (2007) Non-canonical activation of GLI transcription factors: Implications for targeted anti-cancer therapy. Cell Cycle, 6, 2458–2463.
47. Liersch, R., Gerss, J., Schliemann, C., Bayer, M., Schwöppe, C., Biermann, C., Appelmann, I., Kessler, T., Löwenberg, B., Büchner, T., Hiddemann, W., Müller-Tidow, C., Berdel, W. & Mesters, R. (2012) Osteopontin is a prognostic factor for survival of acute myeloid leukemia patients. Blood, 119, 5215–5220.
48. Lim, Y. & Matsui, W. (2010) Hedgehog signaling in hematopoiesis. Critical Reviews in Eukaryotic Gene Expression, 20, 129–139.
49. Lin, T. & Matsui, W. (2012) Hedgehog pathway as a drug target: smoothened inhibitors in development. OncoTargets and Therapy, 5, 47–58.
50. Liu, S., Dontu, G., Mantle, I., Patel, S., Ahn, N., Jackson, K., Suri, P. & Wicha, M. (2006) Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Research, 66, 6063–6071.
51. Liu, Z., Xu, J., He, J., Zheng, Y., Li, H., Lu, Y., Qian, J., Lin, P., Weber, D., Yang, J. & Yi, Q. (2014) A critical role of autocrine sonic hedgehog signaling in human CD138 + myeloma cell survival and drug resistance. Blood, 124, 2061–2071.
52. Long, B., Zhu, H., Zhu, C., Liu, T. & Meng, W. (2011) Activation of the hedgehog pathway in chronic myelogeneous leukemia patients. Journal of Experimental and Clinical Cancer Research, 30, 8.
53. Long, J., Li, B., Rodriguez-Blanco, J., Pastori, C., Volmar, C., Wahlestedt, C., Capobianco, A., Bai, F., Pei, X., Ayad, N. & Robbins, D. (2014) The BET bromodomain inhibitor I-BET151 acts downstream of Smoothened to abrogate the growth of Hedgehog driven cancers. Journal of Biological Chemistry, 289, 35494–35502.
54. Mar, B., Amakye, D., Aifantis, I. & Buonamici, S. (2001) The controversial role of the Hedgehog pathway in normal and malignant hematopoiesis. Leukemia, 25, 1665–1673.
55. Martin, S., Sato, N., Dhara, S., Chang, R., Hustinx, S., Abe, T., Maitra, A. & Goggins, M. (2005) Aberrant methylation of the Human Hedgehog interacting protein (HHIP) gene in pancreatic neoplasms. Cancer Biology & Therapy., 4, 728–733.
56. Merchant, A., Joseph, G., Wang, Q., Brennan, S. & Matsui, W. (2010) Gli1 regulates the proliferation and differentiation of HSCs and myeloid progenitors. Blood, 115, 2391–2396.
57. Minami, Y., Fukushima, N. & Naoe, T. (2013) Effect of treatment with hedgehog inhibitor, PF-04449913, on leukemia-initiation potential in acute myeloid leukemia cells. Journal of Clinical Oncology 31, 15 suppl. (May 20 Supplement) (suppl; abstract e13520).
58. Murone, M., Rosenthal, A. & de Sauvage, F.J. (1999) Hedgehog signal transduction: from flies to vertebrates. Experimental Cell Research, 253, 25–33.
59. Nakamura, K., Sasajima, J., Mizukami, Y., Sugiyama, Y., Yamazaki, M., Fujii, R., Kawamoto, T., Koizumi, K., Sato, K., Fujiya, M., Sasaki, K., Tanno, S., Okumura, T., Shimizu, N., Kawabe, J., Karasaki, H., Kono, T., Li, M., Bardeesy, N., Chung, D. & Kohgo, Y. (2010) Hedgehog promotes neovascularization in pancreatic cancers by regulating Ang-1 and IGF-1 expression in bone-marrow derived pro-angiogenic cells. PLoS ONE, 5, e8824.
60. Nusslein-Volhard, C. & Wieschaus, E. (1980) Mutations affecting segment number and polarity in Drosophila. Nature, 287, 795–80.
61. Pan, D., Li, Y., Li, Z., Wang, Y., Wang, P. & Liang, Y. (2012) Gli inhibitor GANT61 causes apoptosis in myeloid leukemia cells and acts in synergy with rapamycin. Leukemia Research, 36, 742–748.
62. Passamonti, F., Maffioli, M., Cervantes, F., Vannucchi, A., Morra, E., Barbui, T., Caramazza, D., Pieri, L., Rumi, E., Gisslinger, H., Knoops, L., Kiladjian, J., Mora, B., Hollaender, N., Pascutto, C., Harrison, C. & Cazzola, M. (2014) Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts. Blood, 1 23, 1833–1835.
63. Peacock, C., Wang, Q., Gesell, G., Corcoran-Schwartz, I., Jones, E., Kim, J., Devereux, W.L., Rhodes, J.T., Huff, C.A., Beachy, P.A., Watkins, D.N. & Matsui, W. (2007) Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma. PNAS, 104, 4048–4053.
64. Riobo, N.A., Lu, K., Ai, X., Haines, G.M. & Emerson, C.P. (2006) Phosphoinositide 3-kinase and Akt are essential for Sonic Hedgehog signaling. Proceedings of National Academy of Science of The United States of America, 103, 4505–4510.
65. Schnidar, H., Eberl, M., Klingler, S., Mangelberger, D., Kasper, M. & Hauser-Kronberger, C. (2009) Epidermal growth factor receptor signaling synergizes with Hedgehog/GLI in oncogenic transformation via activation of the MEK/ERK/JUN pathway. Cancer Research, 69, 1284–1292.
66. Seke Etet, P., Vecchio, L. & Nwabo Kamdje, A. (2012) Interactions between bone marrow stromal microenvironment and B-chronic lymphocytic leukemia cells: any role for Notch, Wnt and Hh signaling pathways? Cellular Signalling, 24, 1433–1443.
67. Sengupta, A., Banerjee, D., Chandra, S., Banerji, S., Ghosh, R., Roy, R. & Banerjee, S. (2007) Deregulation and cross talk among Sonic hedgehog, Wnt, Hox and Notch signaling in chronic myeloid leukemia progression. Leukemia, 21, 949–955.
68. Shah, N., Cortes, J., Martinelli, G., Smith, D., Clarke, E., Copland, M., Strauss, L. & Talpaz, M. (2014) Dasatinib plus smoothened (SMO) Inhibitor BMS-833923 in Chronic myeloid leukemia (CML) with Resistance or suboptimal response to a prior tyrosine kinase inhibitor (TKI): phase I study CA180323. Blood, 124, 4539.
69. Shaw, A., Gipp, J. & Bushman, W. (2009) The Sonic Hedgehog pathway stimulates prostate tumor growth by paracrine signaling and recapitulates embryonic gene expression in tumor myofibroblasts. Oncogene, 28, 4480–4490.
70. Siggins, S., Nguyen, N., McCormack, M., Vasudevan, S., Villani, R., Jane, S., Wainwright, B. & Curtis, D. (2009) The Hedgehog receptor Patched1 regulates myeloid and lymphoid progenitors by distinct cell-extrinsic mechanisms. Blood, 114, 995–1004.
71. Singh, R., Kim, J., Davuluri, Y., Drakos, E., Cho-Vega, J., Amin, H. & Vega, F. (2010) Hedgehog signaling pathway is activated in diffuse large B-cell lymphoma and contributes to tumor cell survival and proliferation. Leukemia, 24, 1025–1036.
72. Su, W., Meng, F., Huang, L., Zheng, M., Liu, W. & Sun, H. (2012) Sonic hedgehog maintains survival and growth of chronic myeloid leukemia progenitor cells through β-catenin signaling. Experimental Hematology, 40, 418–427.
73. Taipale, J. & Beachy, P.A. (2001) The hedgehog and wnt signalling pathways in cancer. Nature, 411, 349–354.
74. Trowbridge, J., Scott, M. & Bhatia, M. (2006) Hedgehog modulates cell cycle regulators in stem cells to control hematopoietic regeneration. Proceedings of National Academy of Science of The United States of America, 103, 14134–14139.
75. Trudel, G., Paliwal, P. & Lainas, I. (2012) Dasatinib plus SMO antagonist versus dasatinib alone for treating patients (pts) with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in chronic phase (CML-CP): design of CA180-363, a phase II, open-label randomized trial. Journal of Clinical Oncology, 30, 15 suppl. (May 20 Supplement), (suppl; abstr TPS6634).
76. Vannucchi, A., Kiladjian, J., Griesshammer, M., Masszi, T., Durrant, S., Passamonti, F., Harrison, C., Pane, F., Zachee, P., Mesa, R., He, S., Jones, M., Garrett, W., Li, J., Pirron, U., Habr, D. & Verstovsek, S. (2015) Ruxolitinib versus standard therapy for the treatment of polycythemia vera. New England Journal of Medicine, 372, 426–435.
77. Varjosalo, M. & Taipale, J. (2008) Hedgehog: functions and mechanisms. Genes & Development, 22, 2454–2472.
78. Von Hoff, D., LoRusso, M., Rudin, M., Reddy, C., Yauch, R., Tibes, R., Weiss, G., Borad, M., Hann, C., Brahmer, J., Mackey, H., Lum, B., Darbonne, W., Marsters, J., De Sauvage, F. & Low, J. (2009) Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. New England Journal of Medicine, 361, 1164–1172.
79. Wang, Y., Ding, Q., Yen, C., Xia, W., Izzo, J., Lang, J., Li, J., Hsu, J., Miller, J., Wang, X., Lee, D., Hsu, J., Huo, L., LaBaff, A., Liu, D., Huang, T., Lai, C., Tsai, F., Chang, W., Chen, C., Wu, T., Buttar, N., Wang, K., Wu, Y., Wang, H., Ajani, J. & Hung, M. (2012) The crosstalk of mTOR/S6K1 and Hedgehog pathways. Cancer Cell, 21, 374–387.
80. Wellbrock, J., Koehler, J., Wagner, K., Latuske, E., Stamm, H., Vettorazzi, E., Vohwinkel, G., Klokow, M., Kuhling-Thees, R., Loges, S., Amling, M., Bokemeyer, C., Heuser, M., Krauter, J. & Fiedler, W. (2013) Expression of hedgehog pathway mediator Gli2 represents a clinically negative prognostic marker in acute myeloid leukemia and its inhibitor GANT61 exerts anti-leukemic effects in vitro. Blood, 122, 53.
81. Xavier, J., Duarte, A., Pericole, F., Traina, T., Vassllo, J. & Saad, S. (2013) Hedgehog pathway is deregulated in myelodysplastic syndrome progenitor bone marrow cells. Blood, 122, 1533.
82. Yauch, R., Gould, S., Scales, S., Tang, T., Tian, H., Ahn, C., Marshall, D., Fu, L., Januario, T., Kallop, D., Nannini-Pepe, M., Kotkow, K., Marsters, J., Rubin, L. & de Sauvage, F. (2008) A paracrine requirement for hedgehog signalling in cancer. Nature, 455, 406–410.
83. Yauch, R., Dijkgraaf, G., Alicke, B., Januario, T., Ahn, C., Holcomb, T., Pujara, K., Stinson, J., Callahan, C., Tang, T., Bazan, J., Kan, Z., Seshagiri, S., Hann, C., Gould, S., Low, J., Rudin, C. & de Sauvage, F. (2009) Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science, 326, 572–574.
84. Zahreddine, H., Culjkovic-Kraljacic, B., Assouline, S., Gendron, P., Romeo, A., Morris, S., Cormack, G., Jaquith, J., Cerchietti, L., Cocolakis, E., Amri, A., Bergeron, J., Leber, B., Becker, M., Pei, S., Jordan, C., Miller, W. & Borden, K. (2014) The sonic hedgehog factor GLI1 imparts drug resistance through inducible glucuronidation. Nature, 511, 90–93.
85. Zhao, C., Chen, A., Jamieson, C., Fereshteh, M., Abrahamsson, A., Blum, J., Kwon, H., Kim, J., Chute, J., Rizzieri, D., Munchhof, M., VanArsdale, T., Beachy, P. & Reya, T. (2009) Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature, 458, 776–779.
86. Zingariello, M., Martelli, F., Ciaffoni, F., Masiello, F., Ghinassi, B., D'Amore, E., Massa, M., Barosi, G., Sancillo, L., Li, X., Goldberg, J., Rana, R. & Migliaccio, A. (2013) Characterization of the TGF-β1 signaling abnormalities in the Gata1low mouse model of myelofibrosis. Blood, 121, 3345–3363.